Objectives: The effectiveness of endovascular brachytherapy (EVBT) for in-stent restenosis (ISR) after percutaneous transluminal angioplasty (PTA) and stenting (PTAS) has been limited by edge stenosis and late thrombosis. We evaluated a novel protocol of PTA and EVBT for ISR in lower extremity occlusive disease.
Introduction: Neointimal hyperplasia is the leading cause of vein graft failure. Interventions aimed at inhibiting smooth muscle proliferation have not succeeded in human studies. Eph-B4 induces venous identity, and its expression is lost during venous adaptation. Previous studies have demonstrated that exogenous stimulation of Eph-B4 with its ligand Ephrin-B2 reduces neointimal hyperplasia during murine vein graft adaptation. However, it is not known whether this pathway is active and can be manipulated in human vein grafts. Thus our objective was to demonstrate that activation of Eph-B4 with exogenous Ephrin-B2/Fc would reduce neointimal hyperplasia in human saphenous veins in an in vitro model of neointimal hyperplasia.
Methods: Excess saphenous vein was obtained from patients undergoing bypass surgery. Vein rings were cultured for 14 days with Ephrin-B2/Fc at concentrations between 0 and 2 ug/mL. Each ring was compared with its matched control for development of intimal hyperplasia and quantitative real-time polymerase chain reaction was performed to assess gene expression. Human umbilical vein endothelial cells were treated with Ephrin-B2/Fc and receptor phosphorylation was detected with western blot.
Results: Treatment of vein rings with Ephrin-B2/Fc led to an average of 30.8% (95% confidence interval, 6.56-55.0; n ¼ 20) decrease in neointimal hyperplasia compared with controls. Eph-B4 and ephrin-B2 expression significantly decreased in organ culture while osteopontin expression increased (n ¼ 7). Cultured endothelial cells demonstrated a significant increase in Eph-B4 phosphorylation when treated with Ephrin-B2/Fc as well as increased phosphorylated of downstream signaling proteins AKT and ERK.
Conclusions: The Eph-B4 signaling pathway is active in human venous cells and stimulation of Eph-B4 in vitro leads to reduced neoimtimal hyperplasia in saphenous vein rings. Stimulation of the Eph-B4 pathway may be a promising candidate for a clinical trial to reduce vein graft neointimal hyperplasia. Objectives: Supervised exercise (SE) is an evidence-based treatment for intermittent claudication (IC). While primary stenting (PS) for iliofemoral occlusive disease may improve outcomes over angioplasty alone, it may do so at increased cost. Although prior reports have failed to show superiority of angioplasty over SE, we hypothesize that PS is cost-effective when compared with SE. 
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